Hypothesizing that SASP reprogramming with KRT19 knockdown in NSCLC cells might benefit anti-PD-1 immunotherapy, we stably silenced Krt19 using lentiviral particles in LLC cells and subcutaneously injected control or Krt19-knockdown LLC cells into the C57BL/6J mice, followed by treatment with anti-PD-1 (200 μg) or control IgG every three days (Fig. 9A-B). This evidence concerns the gene KRT19 and non-small cell lung carcinoma.